Krystal Biotech Gains UK MHRA Approval for Vyjuvek, Expanding Global Reach but Fundamental Concerns Remain

What happened

Krystal Biotech announced that the UK MHRA approved Vyjuvek for DEB from birth, making it the first genetic medicine approved in the UK for this condition. This follows prior approvals in the US, EU, and Japan, and adds another geography to Vyjuvek's commercial footprint. While the approval is a positive regulatory milestone, the UK market is relatively small and pricing negotiations will still be needed. The stock already trades at a premium valuation (~40x P/E) that embeds expectations for continued global expansion, so this event alone does not materially alter the risk-reward. The core thesis remains that Vyjuvek faces maturing US uptake and uncertain European pricing outcomes.

Implication

The UK approval incrementally supports Vyjuvek's global franchise narrative but does not address the fundamental risks of US market saturation and European pricing compression that underpin our POTENTIAL SELL rating. Without a material change in Vyjuvek's growth trajectory or pipeline de-risking, the risk-reward remains unfavorable at current levels. Investors should view this as an expected step and not a catalyst for re-rating.

Thesis delta

UK approval adds a new market but does not shift the thesis; Vyjuvek's growth challenges in the US and pricing uncertainty in Europe remain the dominant drivers. The incremental revenue from the UK is likely modest and already factored into consensus expectations.